Pharmacological management of primary open-angle glaucoma: second-line options and beyond.

Drugs & Aging
Carroll A B WebersJan S A G Schouten

Abstract

Glaucoma is one of the leading causes of blindness worldwide. Increased intraocular pressure (IOP) is considered to be the most important risk factor. Major outcome studies from recent years have shown that lowering IOP is beneficial in primary open-angle glaucoma and ocular hypertension. The introduction of new classes of IOP-lowering drugs (alpha(2)-adrenoceptor agonists, topical carbonic anhydrase inhibitors and hypotensive lipids) in the last decade has contributed to a change in the drug prescription pattern. Together with beta-adrenoceptor antagonists (beta-blockers), these drugs are now considered to be first-choice classes, giving ophthalmologists ample opportunities to choose from a broad spectrum of IOP-lowering drugs. The number of possible medical treatment combinations has increased likewise.We review medical treatment combinations of two, three or four drugs from the four major first-choice glaucoma drug classes and provide an overview of the scientific evidence for IOP efficacy of second-line medical options when first-line therapy has been effective but additional IOP lowering is necessary. A systematic search of the literature initially revealed 2729 publications. After a thorough selection process, 42 studies ...Continue Reading

References

Dec 28, 1999·American Journal of Ophthalmology·W C StewartJ A Stewart
Feb 9, 2000·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·K H Emmerich
Jul 20, 2000·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·M Diestelhorst
Jun 13, 2001·Acta Ophthalmologica Scandinavica·A M BronM Johansson
Dec 4, 2001·American Journal of Ophthalmology·S Orengo-NaniaUNKNOWN Travoprost Study Group
May 31, 2002·American Journal of Ophthalmology·Anastasios G P KonstasWilliam C Stewart
Jul 6, 2002·Archives of Ophthalmology·Eve J HigginbothamUNKNOWN Fixed Combination Investigative Group
Dec 18, 2002·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Norbert Pfeiffer, UNKNOWN European Latanoprost Fixed Combination Study Group
Apr 26, 2003·The British Journal of Ophthalmology·A HommerUNKNOWN Unoprostone Adjunctive Therapy Study Group
Mar 17, 2004·Current Opinion in Ophthalmology·Robert D Fechtner, Tony Realini
Feb 19, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Faruk OztürkSevim Yaman
Apr 29, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Hidetoshi TsukamotoHiromu K Mishima
Jul 5, 2005·BMJ : British Medical Journal·Philip C MaierYngve T Falck-Ytter
Sep 2, 2005·Clinical Evidence·Rajiv Shah, Richard Wormald

❮ Previous
Next ❯

Citations

Oct 21, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Brian D Hudson, Melanie E M Kelly
Mar 1, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Anton Hommer
Mar 29, 2011·Survey of Ophthalmology·Amar U KishanLawrence S Morse
Feb 24, 2009·Bioorganic & Medicinal Chemistry Letters·Elena PerrinoAnna Sparatore
Sep 11, 2009·Autonomic & Autacoid Pharmacology·P J Fitzgerald
Jun 29, 2017·Expert Opinion on Drug Safety·Jed Asher Lusthaus, Ivan Goldberg
Jun 29, 2017·Journal of Pineal Research·Almudena CrookeJesús Pintor
Jan 4, 2018·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sang Wook Jin, Sae Mi Lee
Mar 17, 2015·The Cochrane Database of Systematic Reviews·Manuele MichelessiTianjing Li
Oct 28, 2018·Ophthalmology and Therapy·Reza Moosavi, Ejaz Ansari
Oct 26, 2014·The Journal of Pharmacology and Experimental Therapeutics·Fernando Huete-ToralJesús Pintor
Sep 1, 2018·Vestnik oftalmologii·S Yu PetrovA V Volzhanin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.